Among all 988 patients, EP/EC (etoposide and cisplatin/carboplatin) was the most often used initial chemotherapy regimen (815 patients). A total of 11 patients received etoposide only according to their physical conditions. In the early period, non EP regimens were administered according to the guidelines or clinician's decision at that time: IP (irinotecan, cisplatin) in 52 patients, CAV (cyclophosphamide, doxorubicin, vincristine) in 39 patients, CODE (cyclophosphamide, doxorubicin, vincristine, etoposide) in 13 patients, paclitaxel plus cisplatin in 27 patients, topotecan in 17 patients, GP (gemcitabine, cisplatin) in five patients, vincristine plus etoposide in four patients, vincristine plus cisplatin in three patients, paclitaxel plus doxorubicin in one patient, and teniposide plus cisplatin in one patient.

Radiotherapy was the main local treatment administered to 627 patients. Only 16 patients received other local treatment such as radiofrequency ablation (12 patients), and surgery (four patients) for palliative purposes. Radiotherapy for thoracic lesions was given as 60–66 Gy (1.8 Gy daily) or 45 Gy (1.5 Gy twice daily) for LS‐SCLC, while 55–60 Gy (1.8 Gy daily) was given for ES‐SCLC. Patients with LS‐SCLC were given concurrent thoracic radiotherapy no later than the beginning of the third cycle of chemotherapy, or sequential radiotherapy depending on performance status. After primary treatment, prophylactic cranial irradiation (PCI), 25 Gy in 10 daily fractions, was given to patients with PR/CR for primary systemic therapy when cranial magnetic resonance imaging (MRI) (contrast computed tomography [CT] when MRI could not be tolerated) revealed no brain metastases. Patients with ES‐SCLC received thoracic radiotherapy selectively when they had finished first‐line chemotherapy and achieved a partial or complete response. Whole brain radiotherapy (WBRT) (30 Gy in 10 daily fractions) and stereotactic radiosurgery (SRS) were used in patients with brain metastases. Irradiation of other metastatic sites was dependent on the location and normal tissue constraints.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.